Literature DB >> 18303855

Structure and inhibition of orotidine 5'-monophosphate decarboxylase from Plasmodium falciparum.

David B Langley1, Maryam Shojaei, Camilla Chan, Hiu Chuen Lok, Joel P Mackay, Thomas W Traut, J Mitchell Guss, Richard I Christopherson.   

Abstract

Orotidine 5'-monophosphate (OMP) decarboxylase from Plasmodium falciparum (PfODCase, EC 4.1.1.23) has been overexpressed, purified, subjected to kinetic and biochemical analysis, and crystallized. The native enzyme is a homodimer with a subunit molecular mass of 38 kDa. The saturation curve for OMP as a substrate conformed to Michaelis-Menten kinetics with K m = 350 +/- 60 nM and V max = 2.70 +/- 0.10 micromol/min/mg protein. Inhibition patterns for nucleoside 5'-monophosphate analogues were linear competitive with respect to OMP with a decreasing potency of inhibition of PfODCase in the order: pyrazofurin 5'-monophosphate ( K i = 3.6 +/- 0.7 nM) > xanthosine 5'-monophosphate (XMP, K i = 4.4 +/- 0.7 nM) > 6-azauridine 5'-monophosphate (AzaUMP, K i = 12 +/- 3 nM) > allopurinol-3-riboside 5'-monophosphate ( K i = 240 +/- 20 nM). XMP is an approximately 150-fold more potent inhibitor of PfODCase compared with the human enzyme. The structure of PfODCase was solved in the absence of ligand and displays a classic TIM-barrel fold characteristic of the enzyme. Both the phosphate-binding loop and the betaalpha5-loop have conformational flexibility, which may be associated with substrate capture and product release along the reaction pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303855     DOI: 10.1021/bi702390k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

Review 1.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Authors:  Margaret A Phillips; Pradipsinh K Rathod
Journal:  Infect Disord Drug Targets       Date:  2010-06

Review 2.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum.

Authors:  Sandhya Kortagere; William J Welsh; Joanne M Morrisey; Thomas Daly; Ijeoma Ejigiri; Photini Sinnis; Akhil B Vaidya; Lawrence W Bergman
Journal:  J Chem Inf Model       Date:  2010-05-24       Impact factor: 4.956

4.  Determination of the amino acid sequence requirements for catalysis by the highly proficient orotidine monophosphate decarboxylase.

Authors:  Ji Yuan; Ana Maria Cardenas; Hiram F Gilbert; Timothy Palzkill
Journal:  Protein Sci       Date:  2011-09-22       Impact factor: 6.725

5.  Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.

Authors:  Lee-Han Kim; Soon Myung Kang; Jake Whang; Kee Woong Kwon; Sung Jae Shin
Journal:  Antimicrob Agents Chemother       Date:  2022-08-30       Impact factor: 5.938

6.  Structural characterization of the molecular events during a slow substrate-product transition in orotidine 5'-monophosphate decarboxylase.

Authors:  Masahiro Fujihashi; Lianhu Wei; Lakshmi P Kotra; Emil F Pai
Journal:  J Mol Biol       Date:  2009-02-21       Impact factor: 5.469

7.  Use of thermal melt curves to assess the quality of enzyme preparations.

Authors:  Gregory J Crowther; Panqing He; Philip P Rodenbough; Andrew P Thomas; Kuzma V Kovzun; David J Leibly; Janhavi Bhandari; Lisa J Castaneda; Wim G J Hol; Michael H Gelb; Alberto J Napuli; Wesley C Van Voorhis
Journal:  Anal Biochem       Date:  2009-12-14       Impact factor: 3.365

Review 8.  The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking Investigations.

Authors:  Ifedayo Victor Ogungbe; William N Setzer
Journal:  Molecules       Date:  2016-10-19       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.